These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21685202)
1. Peripheral neuropathy in patients on long-term triazole antifungal therapy. Baxter CG; Marshall A; Roberts M; Felton TW; Denning DW J Antimicrob Chemother; 2011 Sep; 66(9):2136-9. PubMed ID: 21685202 [TBL] [Abstract][Full Text] [Related]
2. [Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis]. Gendrot A; de La Blanchardière A; de La Gastine B; Fromager G; Massias L; Verdon R Rev Med Interne; 2010 Feb; 31(2):163-6. PubMed ID: 19457596 [TBL] [Abstract][Full Text] [Related]
3. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Sambatakou H; Dupont B; Lode H; Denning DW Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972 [TBL] [Abstract][Full Text] [Related]
4. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Chishimba L; Niven RM; Cooley J; Denning DW J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765 [TBL] [Abstract][Full Text] [Related]
5. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B; N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683 [TBL] [Abstract][Full Text] [Related]
11. Successful early voriconazole treatment of Aspergillus infection in two non immunocompromised patients in Intensive Care Unit. Nataloni S; Gabbanelli V; Rossi R; Donati A; Pantanetti S; Pelaia P Minerva Anestesiol; 2007 Jun; 73(6):371-5. PubMed ID: 17072284 [TBL] [Abstract][Full Text] [Related]
12. Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population. Yang T; Wu XM; Qiu HQ; Fu DH; Hu JD; Li J; Zheng XY; Luo XF; Yuan XH; Chen RL; Chen ZZ Clin Transplant; 2013; 27(2):255-60. PubMed ID: 23294039 [TBL] [Abstract][Full Text] [Related]
13. A case series of unilateral orbital aspergillosis in three cats and treatment with voriconazole. Smith LN; Hoffman SB Vet Ophthalmol; 2010 May; 13(3):190-203. PubMed ID: 20500720 [TBL] [Abstract][Full Text] [Related]
14. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306 [TBL] [Abstract][Full Text] [Related]
15. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. Pakyz A; Bearman G Consult Pharm; 2008 Oct; 23(10):804-8. PubMed ID: 19032016 [TBL] [Abstract][Full Text] [Related]
20. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]